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Abstract
Purpose: It is known that major histocompatibility complex class II protein HLA-DR is highly
expressed in B-cell lymphomas and in a variety of autoimmune and inflammatory diseases.
Therefore, a radiolabelled fully humanized IgG4 monoclonal antibody (mAb) can provide useful
prognostic and diagnostic information. Aims of the present study were to radiolabel an anti-HLA-
DR mAb with technetium-99m and to evaluate its binding specificity, tissue distribution and
targeting potential.
Procedures: For labelling, we compared a direct method, after 2-mercaptoethanol (2-ME)
reduction of disulphide bonds, with a two-step labelling method, using a heterobifunctional
succinimidyl-6-hydrazinonicotinate hydrochloride chelator. Several in vitro quality controls and in
vivo experiments in mice were performed.
Results: We obtained highest labelling efficiency (LE, 998%) and specific activity (SA;
5,550 MBq/mg) via the direct method. In vitro quality control showed good stability, structural
integrity and retention of the binding properties of the labelled mAb. The biodistribution in mice
showed high and persistent uptake in spleen and suggests kidney and liver-mediated clearance
pathways. In tumour targeting experiments, we observed high uptake in HLA-DR-positive
xenografts compared to controls. In vivo binding was proportional to the number of injected cells.
In the in vivo blocking assay, uptake of radiolabelled mAb was significantly decreased in mice
pre-injected with 100-fold molar excess of unlabelled mAb.
Conclusion: We efficiently labelled a humanized anti-HLA-DR mAb with
99mTc using a direct
labelling method. Radiolabelled mAb binds to human HLA-DR antigens and therefore warrants
further evaluation as a prognostic and diagnostic tool for patients with lymphoma or autoimmune
diseases.
Key Words: Anti-HLA-DR monoclonal antibody, 1D09C3, Lymphoma, Autoimmune disease,
Radiolabelling, Molecular imaging
Introduction
T
he major histocompatibility complex (MHC) consists of
membrane-bound glycoproteins that are involved in
different immunological and non-immunological phenomena
[1]. In humans, MHC class I genes, consisting of the three
loci HLA-A, B and C, are expressed on almost all cells. In
contrast, MHC class II genes, which encode for HLA-DR,
DQ and DP antigens, are expressed mainly on B lympho-
cytes, activated T lymphocytes, macrophages, monocytes,
dendritic cells, activated NK cells and progenitor haemo-
poietic cells. HLA-DR molecules are composed of α (35kD) Correspondence to: Gaurav Malviya; e-mail: gaurav.malviya@yahoo.com
The Author(s), 2010and β (28kD) subunits. Each subunit contains two extrac-
ellular domains, a membrane-spanning domain and a
cytoplasmic tail. In mice, two subclasses, H2-A (HLA-DQ
homologue) and H2-E (HLA-DR homologue), are known,
and both are functional [2–4]. Delovitch et al. demonstrated
that mouse anti-Ia alloantisera apparently react more
strongly with human Ia antigens than do human alloantisera,
therefore it is reasonable that a mice model could be used to
study the functional properties of human Ia antigens, which
are coded by MHC-II [5, 6].
The HLA-DR antigens play important roles in the cellular
interaction involved in immune response. The HLA-DR
protein is an intermediate activation antigen that is expressed
onthesurfaceofCD4andCD8-positiveTcellsinthecourseof
lymphocyte activation. In the resting state of T lymphocytes,
HLA-DR is not expressed and istherefore a specific biomarker
for T cell activation. This activation antigen is expressed on a
high percentage of tissue infiltrating lymphocytes for a longer
time span than other activation markers, such as CD25 (the IL-
2 receptor), VLA antigens and 4F2 antigens. It is therefore a
suitable target for nuclear imaging with a radioactive probe for
the in vivo detection of T cell-mediated inflammation, includ-
ing autoimmune diseases.
It is also known that other cells, such as vessel
endothelium, may express HLA-DR following the release
of local inflammatory molecules. Isobe and co-workers
found the expression of MHC class II antigens in an animal
model of heart rejection and also in kidney allograft
rejection using an
111Indium-labelled anti-MHC class II
antigen monoclonal antibody (mAb) [7, 8]. Indeed, scintig-
raphy and histological examination revealed the presence of
MHC class II antigen (HLA-DR) molecules on both the graft
endothelium and the infiltrating mononuclear cells.
As far as malignancies are concerned, an abnormal HLA-
DR expression has been demonstrated on the cell surface of
several cancer types, mainly on leukemia and lymphoma
cells. Loss of MHC-II molecules on diffuse large B-cell
lymphoma (DLBCL) has been associated with poor survival.
Recently, Rimsza et al. (2007) demonstrated that the HLA-
DR protein status can predict the survival in patients with
DLBCL treated with the MACOP-B chemotherapy regimen
and therefore can be used as a prognostic marker [9]. Other
authors outlined the effect of tumour cell MHC antigens on
cytotoxic T lymphocytes (CTL) induction. Both MHC class
I and class II antigens on the head and neck tumour cells
were shown to play a critical role in inducing CTL [10].
A fully humanized IgG4 mAb named 1D09C3 discovered
by screening the Morphosys Human Combinatorial Anti-
body Library, a diverse library of single-chain antibody
variable fragments, was constructed by combining highly
variable complementarity determining regions [11]. IgG4
antibodies differ functionally from other IgG subclasses by
their poor ability to stimulate the complement system thus
minimizing side effects due to Fc-portion-mediated effector
functions [12, 13]. Studies showed its in vivo as well as in
vitro tumouricidal activity and described that it acts
selectively on tumour-transformed and activated cells via a
non-apoptotic mechanism [14, 15]. It has been shown that
the HLA-DR protein status predicts survival in patients with
B-cell lymphoma, but little is known whether it is possible to
obtain this information in vivo by non-invasive imaging
modalities. Moreover, patient variability in HLA-DR expres-
sion on both cancer cells and inflammatory cells is unclear.
These facts highlight the opportunity to use a radiolabelled
anti-HLA-DR monoclonal antibody probe for in vivo study-
ing of the tumour selectivity of the mAb and patient
variability in HLA-DR expression on tumour cells. Such a
probe would also allow non-invasive evaluation of disease
extent and severity in both B-cell lymphoma patients and
patients affected by autoimmune diseases. This method
could be useful for monitoring the efficacy of several
therapies in autoimmune diseases and in cancer patients,
particularly in those patients that are treated with unlabelled
anti-HLA-DR antibodies.
Materials and Methods
Antibodies
Anti-HLA-DR mAb (1D09C3) was kindly provided by GPC
Biotech, Germany. We tried both, direct and indirect, radiolabelling
methods to label anti-HLA-DR mAb with
99mTc in order to obtain
a high labelling efficiency (LE) and specific activity (SA) without
any modification in biological specificity of the antibody.
Labelling of Anti-HLA-DR mAb with
99mTc
by the Indirect Heterobifunctional Linker Method
Indirect labelling of anti-HLA-DR mAb was performed by
conjugation of the mAb with the heterobifunctional linker
succinimidyl-6-hydrazinonicotinate hydrochloride (SHNH). In
brief, of SHNH (SoluLink, USA; 100 mM in DMF) was added
dropwise at different molar ratios to a stirred solution of antibody
(20 mM) in 100 mM of sodium phosphate/150 mM of NaCl buffer
solution pH 7.6–8.0. The mixture was purified by G-25 Sephadex
PD10 column chromatography (GE Healthcare, Sweden) using
nitrogen-purged cold phosphate-buffered saline (pH 7.4) as eluent.
To label the mAb–SHNH complex efficiently with
99mTc, to
minimize the percentage of colloid formation and to optimize the
influence of the amount of co-ligand on the LE, titrations of tricine
(100 mg/mL, Sigma-Aldrich Chemicals, UK) and SnCl2 (2 mg/mL
in 0.1 M HCl, Sigma-Aldrich Chemicals, UK) were performed with
mAb–SHNH complex (100 μg) in 1 M sodium acetate (pH 5.5)
using 520–555 MBq of freshly eluted
99mTcO4
− (100 μL) while
keeping the volume of the reaction constant.
Labelling of Anti-HLA-DR mAb with
99mTc
by the Direct 2-Mercaptoethanol Reduction Method
The anti-HLA-DR mAb was also tested for labelling with
99mTc
using the 2-mercaptoethanol (2-ME) reduction method as described
by Mather and Ellison [16]. Briefly, the disulfide bridges of the
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ratios (1,000: 1; 2,000: 1 and 4,000: 1) in order to achieve the best
activation of the antibody and consequently the highest LE. The
activated antibody was then purified using G-25 Sephadex PD10
column chromatography and nitrogen-purged cold phosphate-
buffered saline (pH 7.4) as eluent. Methylene diphosphonic acid
(MDP) was used as a weak competitive ligand. The bone scan kit
(Amersham, UK), containing 10 mg of methylene diphosphonic acid,
0.17 mg of SnCl2 and 2 mg of ascorbic acid, was reconstituted with
1 mL of nitrogen-purged saline. Different amounts (from 1 to7 μL)of
the methylene diphosphonate solution were tested with 100 μgo f
activated antibodies, using 520–555 MBq of
99mTcO4
− freshly eluted
from a
99Mo/
99mTc generator in order to achieve the highest LE.
Radiochemical Purity of
99mTc-anti-HLA-DR mAb
Quality controls were performed using instant thin layer chromatog-
raphy-silica gel (ITLC-SG) strips (VWR International, Italy). The
strips were analyzed with a radio scanner (Bioscan Inc., USA) to
quantitate the percentage of activity bound to the antibody. When
0.9% NaCl was used as the solvent (with normal ITLC-SG strips),
retention factors (Rf) were
99mTc-labelled antibody=0.0,
99mTc-
tricine,
99mTc-MDP and free
99mTcO4
−=0.9–1.0. When NH3 to H2O
toEtOH(1: 5: 2)was used as the solventand albuminabsorbed ITLC-
SG strips, Rf values were
99mTc-colloids=0.0,
99mTc-labelled anti-
body=1.0,
99mTc-tricine and free
99mTcO4
−=0.9–1.0.
Stability and Structural Integrity of
99mTc-anti-
HLA-DR mAb
The stability of the labelled antibody was measured in human
serum and in normal saline at 37°C up to 20 h. To obtain human
blood serum, 5 mL of blood was collected in a vial without any
anticoagulant and was left at room temperature for 30 min in a
vertical position for clotting. Then the vial was centrifuged at 20°C,
1,500 g for 10 min, and the serum was removed gently the from
cell pellet. One hundred microlitres of
99mTc-anti-HLA-DR mAb
was added to 900 μL of fresh human blood serum or normal saline
and was incubated at 37°C. The percentages of free
99mTc and
antibody-bound radioactivity were measured at different time
points (1, 3, 6 and 20 h) by ITLC-SG.
In addition, a cysteine challenge assay was performed to check the
in vitro stability of the radiolabelled antibody. The
99mTc-anti-HLA-
DR mAb was incubated at 37°C for 60 min at different cysteine to
mAb molar ratios, which ranged from 500:1 at the highest cysteine
concentration to zero in the absence of cysteine. At the end of the
incubation time, each reaction mixture was evaluated by ITLC-SG as
describedabove.Allknownchemicalformsof
99mTc-cysteinehaveRf
values between 0.5 and 1.0, when normal saline is used as the eluent.
Possible modifications induced by the 2-ME reduction proce-
dure on anti-HLA-DR mAb were tested by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) in non-
reducing conditions. Equal amounts of native mAb and radio-
labelled mAb (60 μg) and a protein molecular weight marker (17–
250 kD, Fermentas Life Sciences) were applied to separate slots of
a 8% SDS polyacrylamide gel. The gel was run at 45 mA constant
voltage and subsequently stained with Coomassie Brilliant Blue
G250 (Sigma) for 30 min and distained with a methanol to H2Ot o
acetic acid (4.5: 4.5: 1) solution. Autoradiography of
99mTc-anti-
HLA-DR mAb was also performed to check the incorporation of
radioactivity in the mAb after radiolabelling. For this purpose,
radiolabelled mAb (11.1 MBq) was run in a separate lane of the
SDS-PAGE. The gel was exposed to a photographic plate for
20 min in a cassette (Kodak Biomax) and the photographic plate
was developed subsequently according to standard procedures.
Immunoreactive Fraction Assay
The assay for determination of the fraction of immunoreactive
antibody by linear extrapolation to conditions representing infinite
antigen excess has been adapted with slight modifications from the
method described by Lindmo et al.[ 17].
The immunoreactive fraction assay was performed using a
constant concentration of radiolabelled mAb and serial dilutions of
DAUDI cells, a human lymphocytic Burkitt’s lymphoma cell line.
The cells were washed three times in phosphate-buffered saline
(pH 7.4) and suspended in a cold PBS with 1% BSA. Radiolabelled
mAb at a constant concentration of 50 ng/mL in PBS with 1% BSA
was added to different amounts of cells (concentration ranging from
2.6×10
6 to 0.08×10
6 cells/mL). The cells were incubated for 2 h at
4°C and then washed twice with 500 μL of cold PBS with 1% BSA
before counting cell-associated radioactivity in a single-well
gamma counter (Gammatom s.p.a., Italy). The data were plotted
as a double inverse plot of the applied radiolabelled antibody over
the specific binding, as a function of the inverse cell concentration.
In this plot, the origin of the abscissa represents infinite cell
concentration, i.e., conditions of infinite antigen excess. All
experiments were performed in duplicate.
In Vitro Competitive Binding Assay
HLA-DR positive DAUDI cells were maintained in a RPMI 1640
culture medium (Sigma-Aldrich Chemical, UK) supplemented with
10% foetal calf serum, 2 mM of glutamine, 100 U/mL penicillin
and 100 μg/mL of streptomycin. Cells were cultured at 4–6×10
5
cells/mL at 37°C in a 5% CO2 incubator for 1 week.
A binding assay was performed on DAUDI cells in order to test
the specific binding of labelled anti-HLA-DR mAb. Briefly, 10
6
DAUDI cells were incubated in triplicate with different concen-
trations (from 50 nM to 0.05 nM) of radiolabelled anti-HLA-DR
mAb at 4°C for 90 min. Specific binding was determined by
performing the assay in the presence and absence of a 100-fold
molar excess of unlabelled anti-HLA-DR mAb (500 nM). At the
end of the incubation time, cells were harvested by centrifugation
(5,000 g for 3 min). Each supernatant was collected in separate
vials, then cells and supernatants were counted separately for
radioactivity in a single-well gamma counter. The curve of specific
binding was generated as the difference between total binding and
non-specific binding. A Scatchard analysis was performed using
GraphPad Prism version 5.00 software (GraphPad Software, Inc.)
to determine the dissociation constant (Kd).
Retention Assay (LigandTracer
™ Assay)
Real-time measurements of cellular uptake and retention were
performed using a rotating radioimmuno assay (RIA) in a
LigandTracer
™ instrument (Ridgeview Instruments AB, Uppsala,
932 G. Malviya, et al.: Synthesis of
99mTc-anti-HLA-DR AntibodySweden) [18–20]. HLA-DR positive DAUDI cells were cultured in
complete RPMI medium, as described above. Approximately 10×
10
6 cells were spun down twice in PBS and were resuspended in
approximately 1 mL of PBS. Fibronectin-coated circular plastic
Petri plates (BD BioCoat
™, BD Biosciences) were rinsed twice
with Milli Q water and were left in a tilted position. To activate part
of the dish, 1 mL of 0.20 M N-ethyl-N’-(dimethylaminopropyl)
carbodiimide (Sigma-Aldrich Chemicals, UK) and 0.05 M N-
hydroxysuccinimide (Sigma-Aldrich Chemicals, UK) was added to
the lower part of the dish and incubated at room temperature for
30 min. Then, the dish was rinsed and the cell suspension was
carefullydispensedontotheactivatedsectionofthedish.Thedishwas
p u ti naC O 2 incubator for 1 h, after which 4 mL of complete RPMI
medium was added to the dish and incubated for another hour. The
dish was then placed in the LigandTracer apparatus and rotated
continuously for 1 h to allow release of weakly attached cells. After
one gentle wash, the Petri plate was ready for measurement. Radio-
labelled mAb (0.7 nM) in PBS pH 7.4 supplemented with 7% cell
culture medium devoid of FCS was added. When the radiolabelled
antibody binds to the cells, a detector placed over the elevated part of
the dish registers the cell-bound activity each time the cells pass
throughthedetector.Byfollowingthe(peak)activityovertime,areal-
time binding curve was obtained using a LigandTracer software 1.0
(Ridgeview Instruments AB, Uppsala, Sweden). Retention studies
were performed in two steps. First, radiolabelled anti-HLA-DR mAb
was added tothe Petri plate followed by incubation for 2–4 h.Second,
the assay buffer containing radiolabelled mAb was replaced with an
assay buffer without radiolabelled mAb, after which LigandTracer
was run several hours to follow the retention of the bound material.
We also repeated the experiment with the control cell line TPC1
to compare the uptake and retention properties of the radiolabelled
anti-HLA-DR mAb.
Biodistribution of
99mTc-Labelled Anti-HLA-DR
mAb in Balb/c Mice
The biodistribution of
99mTc-labelled anti-HLA-DR mAb was
studied in nine female Balb/c nude mice of 10–12 weeks (Charles
River Laboratories, USA). The mice were injected i.v. with 10.5–
11.5 MBq (approximately 2 μg) of
99mTc-labelled anti-HLA-DR
mAb. Animals were sacrificed by cervical dislocation after 1 h (n=
3), 3 h (n=3) or 24 h (n=3) and immediately perfused with normal
saline by heart puncture and cutting of the abdominal vein to wash
out all blood from organs and tissues. Major organs (heart, lungs,
liver, spleen, kidney, stomach, small bowel, large bowel, muscle
and bone) were excised, weighted and counted in a single-well
gamma counter. To correct for radioactive decay and permit
calculation of the uptake of the radiopharmaceuticals in each organ
as fraction of the injected dose, an aliquot of the injected dose was
counted simultaneously. Results were expressed as percentage of
the injected dose per gram of tissue±standard deviation (SD). All
animal studies were performed in compliance with the local ethical
committee and according to national regulations.
High Resolution Gamma Camera
The high-resolution gamma camera (HRC) (Li-tech S.r.l., Italy) is
composed of a 30-mm long collimator consisting of 200-μ thick
tungsten blades which form 3×3 mm
2 large square holes, in which
3×3×5 mm
3 CsI(Tl) position sensitive crystals (Spectra Physics-
Hilger Analytical, UK) are inserted. Thus, the crystal-free length of
the holes is 25 mm. The crystal collimator structure is coupled to a
Hamamatsu H8500 (Hamamatsu, Japan) position sensitive photo
multiplier tube (PSPMT), charge readout electronics and a data
acquisition system [21, 22]. The system allows performing real-
time acquisitions with a refresh time of 0.5 s. The HRC energy
resolution is about 20% at 140 keV (
99mTc). The sensitivity is
210 cps/MBq and the uniformity is±5% while it provides a 2.2-mm
intrinsic resolution suitable for our in vivo imaging experiments in
small animals.
In Vivo Targeting Experiment on DAUDI Cells
Xenografted Balb/c Mice
To evaluate the ability of the radiolabelled anti-HLA-DR mAb to
specifically bind to DAUDI cells in vivo, we performed a targeting
experiment in nine nude Balb/c nu/nu mice. The mice were divided in
threegroupsandsubcutaneouslyimplantedwithan increasingnumber
of DAUDI cells in the left shoulder, i.e.,1 0×1 0
6,2 0 ×1 0
6 or 30×10
6
cells, in Matrigel
™ (BD Biosciences, USA). In the right shoulder, the
mice were implanted with same number of a control HLA-DR-
negative cell line. For this control cell line, we used TPC1 cells,
derived from human thyroid papillary cancer [23]. After 2 h, the mice
were injected in the tail vein with 10.5–11.5 MBq (approximately
2 μg) of radiolabelled anti-HLA-DR mAb and high-resolution
gamma-camera images were acquired after 1, 3, 6 and 24 h. Regions
of interest were drawn over the left (target) and right shoulder
(background) and target to background (T/B) ratios were calculated.
In Vivo Blocking of
99mTc-anti-HLA-DR mAb
Binding with Cold Anti-HLA-DR mAb
Eight nude Balb/c nu/nu mice underwent a competition study to
assess to what extent the uptake of
99mTc-labelled anti-HLA-DR
mAb to HLA-DR positive cells could be blocked by an excess of
unlabelled antibody. To this aim, the mice were subcutaneously
implanted with 30×10
6 DAUDI cells in Matrigel
™ in the right
shoulder. As control, the mice were implanted with the same
volume of Matrigel™ without cells in the left shoulder. Four mice
were pre-injected i.v. with a 100-fold excess of unlabelled anti-
HLA-DR mAb immediately before the injection of a tracer dose of
10.5–11.5 MBq (approximately 2 μg) of
99mTc-anti-HLA-DR mAb
in the tail vein. Another group of four mice received only
99mTc-
anti-HLA-DR mAb. High-resolution gamma-camera images were
acquired after 1, 3, 6 and 24 h. Regions of interest were drawn over
the right (target) and left shoulder (background) and T/B ratios
were calculated.
Results
Labelling of Anti-HLA-DR mAb with
99mTc
by the Indirect Heterobifunctional Linker Method
Highest LE efficiency could be obtained when the mAb was
conjugated with SHNH at a 1:20 ratio. Optimization of the
coupling of the mAb–SHNH conjugate (100 μg) with
99mTc
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ofSnCl2(2mg/mL)gavethehighestLEandthelowestamount
of colloids. After 60 min of incubation under these optimized
conditions, we obtained an LE of only 60±5% with a high
percentage of colloids (≥25%). Moreover, the
99mTc-SHNH–
anti-HLA-DR mAb complex also had a low SA (3,000 MBq/
mg). Due to the low LE and high colloid formation of the anti-
HLA-DR mAb, we did not proceed with the indirect labelling
method as the method of choice.
Labelling of Anti-HLA-DR mAb with
99mTc
by the Direct 2-Mercaptoethanol Reduction Method
With the direct labelling method, the best results were
obtained when sulphide bridges of the antibody were
reduced using a 2,000-fold excess of 2-ME. We obtained
the highest LE with negligible amount of colloids when the
activated mAb was labelled with only 3 μL of methylene
diphosphonic acid solution (from the bone scan kit). Using
this radiollabelling method,
99mTc-labelled anti-HLA-DR
mAb could be obtained with a very high LE (998%),
negligible percentage of colloids (G2%) and high SA
(5,550 MBq/mg). Thus, a post-labelling purification step
could be avoided. Indeed, we used this labelling method as a
method of choice for in vitro and in vivo studies.
Stability and Structural Integrity of
99mTc-anti-
HLA-DR mAb
The
99mTc-anti-HLA-DR mAb was stable when incubated in
human serum or in normal saline at 37°C for at least 6 h, as
shown in Fig. 1a. After 20 h, still more than 60% of the
radioactivity was bound to the antibody in both media. The
cysteine challenge assay also demonstrated a very high
stability when the labelled antibody was exposed to up to a
50-fold excess of cysteine, whereas exposure to a 500-fold
excess of cysteine resulted in only a 30% release of mAb-
associated radioactivity (Fig. 1b).
SDS-PAGE analysis of the radiolabelled anti-HLA-DR
mAb showed no significant differences with the native anti-
HLA-DR mAb (Fig. 1c). Native and labelled mAb showed a
band of 166 kDa (i.e., molecular weight of complete mAb);
however, a band of approximately 66 kDa was also present
in both lanes and could be ascribed to one half of the
complete mAb (i.e., heavy–light chain). No other band was
seen in radiolabelled mAb lane. Autoradiographic analysis
of
99mTc-anti-HLA-DR mAb, however, showed that the
radioactivity (
99mTc) was associated with the band of
approximately 166 kD, which corresponds to the molecular
weight of native anti-HLA-DR mAb (Fig. 1c).
Immunoreactive Fraction Assay
The datademonstrate a very closely linearrelationship of‘total
applied/specific binding’ as a function of the inverse cell
concentration. Fitting of a straight line to the data by means of
Fig. 1. a Stability of
99mTc-anti-HLA-DR mAb in saline and
in plasma assessed by ITLC-SG at different time points. b
Cysteine challenge assay of
99mTc-anti-HLA-DR mAb
assessed by ITLC-SG at an increasing ratio between
cysteine and mAb. c SDS-PAGE of native and radiolabelled
anti-HLA-DR mAb and autoradiographic analysis of
99mTc-
anti-HLA-DR mAb.
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nation of the intercept value at the ordinate. This value equals
1/immunoreactive fraction; thus in this case, the percent
immunoreactive fraction equals 86%, as shown in the Fig. 2.
In Vitro Competitive Binding Assay
The saturation binding curve was plotted as specifically bound
radioactivity against the molar concentration of radiolabelled
mAb. This curve showed a plateau (Fig. 3), indicating that the
antibody specifically binds to a target that can be saturated. A
100-fold molar excess of unlabelled antibody saturates the
receptors present on the cells and consequently prevented the
specific binding of the radiolabelled 1D09C3. This shows that
1D09C3 retained its specific binding to HLA-DR receptors
expressed on DAUDI cells, even after the radiolabelling with
technetium-99m. The Kd for
99mTc-1D09C3 was 6.7 nM,
which is comparable to the Kd of native 1D09C3, i.e., 2.9 nM.
Retention Assay (LigandTracer
™ Assay)
Approximately 50% of the total suspended DAUDI cells, i.e.,
5×10
6 cells, were covalently adhered to the fibronectin-coated
plastic Petriplate.The adhesionwas persistentfor atleast 25 h.
Thecurveforcellularuptakeandretentionof
99mTc-anti-HLA-
DR mAb is shown in Fig. 4. When the radiolabelled mAb was
removed from the medium, about 34% of the radioactivity is
released from the cells with a half-life of 0.53 h, whereas
approximately two thirds of the radioactivity remains attached
to the target cells even after 25 h.
When we repeated the experiment with the control cell line
TPC1, we did not find any uptake of
99mTc-labelled anti-HLA-
DR mAb during the 10-h time duration (Fig. 4,i n s e r t ) .
Biodistribution of
99mTc-Labelled Anti-HLA-DR
mAb in Balb/c Mice
The biodistribution study of
99mTc-labelled anti-HLA-DR mAb
performed in nine Balb/c nude mice revealed a high and
persistent uptake in spleen, which could be because of binding
of
99mTc-labelledanti-HLA-DRmAbtosplenicBlymphocytes.
A significant uptake of radiolabelled mAb was also observed in
the liver and kidney, suggesting a mixed hepatic/renal clearance
mechanism of the radiolabelled mAb. The
99mTc-labelled anti-
HLA-DR mAb also shows substantial uptake in the bones and
lungs.Moreover,negligibleaccumulationwasobservedinother
organs and tissues over a period of 24 h (Fig. 5).
In Vivo Targeting Experiment in DAUDI Cells
Xenografted Balb/c Mice
HLA-DR positive cells were detected by high-resolution
gamma-camera imaging in Balb/c mice implanted with an
increasing number of DAUDI cells (Fig. 6a). Quantification
of
99mTc-anti-HLA-DR mAb uptake showed a significant
increase in T/B ratio over time (pG0.05) (Table 1).
WealsofoundastatisticallysignificantincreaseinT/Bratio
with an increasing number of cells xenografted into shoulders
of mice, 10×10
6vs. 20×10
6 injected cells at 1 h (p=0.03) and
a t3h( p=0.01); 20×10
6vs. 30×10
6 injected cells at 3 h (p=
0.003) and at 6 h (p=0.01);10×10
6vs. 30×10
6 injected cells at
In Vivo Blocking of
99mTc-anti-HLA-DR mAb
Binding with Cold Anti-HLA-DR Mab
As shown in Fig. 7a, the uptake of radiolabelled anti-HLA-
DR mAb was significantly reduced after pre-injection of a
100-fold excess of unlabelled anti-HLA-DR mAb. In mice
pre-treated with cold mAb, the radioactivity uptake in the
HLA-DR expressing xenograft was 34% (p=0.34), 90% (p=
0.01), 94% (p=0.02) and 96% (p=0.03) lower than in
control animals at 1, 3, 6 and 24 h after injection of the
radiolabelled antibody, respectively (Fig. 7b).
Discussion
Several studies demonstrated the therapeutic potential of
various anti-HLA-DR mAb, such as Lym-1 [24, 25] and
Fig. 2. A double inverse plot of the immunoreactivity
fraction assay.
Fig. 3. Saturation binding curve of
99mTc labelled anti-HLA-
DR mAb to DAUDI cells. Curve fitting was performed using
GraphPad software.
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1h( p=0.008), at 3 h (p=0.001), at 6 h (p=0.01) and at 24 h
(p=0.02) (Fig. 6b).1D10 [26]; however, previous mAbs were differing in many
aspects from the anti-HLA-DR mAb 1D09C3 that we used
here. The former two antibodies recognize what seem to be
post-translational modifications on HLA-DR molecules that
occur preferentially in B-cell-derived tumours, but also to
some extent in normal B cells [24, 27]. Moreover, Lym-1 is
a murine antibody with substantial immunogenicity for
humans, and 1D10 is a humanized antibody. The anti-
HLA-DR antibody that we have selected is a fully human
antibody with selectivity for activated and/or tumour-trans-
formed cells. This antibody demonstrates a substantially
different binding profile and mechanism of action as
compared to previous anti-HLA-DR antibodies. If radio-
labelled, this anti-HLA-DR mAb may provide a valuable
novel diagnostic and prognostic tool to image the infiltration
of HLA-DR positive cells in autoimmune and lymphoma/
leukemia patients.
We therefore attempt to label anti-HLA-DR mAb with
technetium-99m. We tried both direct and indirect labelling
procedures in order to develop a reliable and simple method
that allows the formation of a stable
99mTc-conjugate with
no modification in its biological activity. The labelling
procedure based on 2-ME activation of the mAb gave the
best results, allowing us to achieve a very high LE (998%)
and a high SA (5,550 MBq/mg) with a negligible presence
of colloids and therefore no need for post-labelling purifi-
cation. The labelled product was stable in normal saline and
serum up to 6 h at 37°C, whereas degradation at 20 h was
still less than 40%, which is sufficient for imaging purposes
in patients. The Kd value of the labelled mAb is in the same
Fig. 4. Binding trace graph (decay-corrected) for uptake and retention of
99mTc-anti-HLA-DR mAb bound to DAUDI cells.
Binding studies were performed in two steps: addition of radiolabelled anti-HLA-DR mAb (Uptake), followed by replacing
radiolabelled mAb with assay buffer without radiopharmaceutical (Retention). Results of the same experiment with TPC1
control cells (inset) did not show any peak for specific uptake of
99mTc-labelled anti-HLA-DR mAb in the uptake phase.
Fig. 5. Biodistribution of
99mTc-labelled anti-DR mAb in Balb/c nude mice at 1, 6 and 24 h post injection.
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which indicates that the biological activity of mAb was not
significantly deteriorated by the labelling procedure. Our
data show that in vitro, the majority of radiolabelled mAb
remains irreversibly bound to the target cells, which is
consistent with the gradual increase in tracer uptake over
time that was observed in vivo.
In the biodistribution experiments, the spleen showed
high and persistent uptake, which was not unexpected
because MHC-II DR antigens that are constitutively
expressed on splenic B lymphocytes; however, we also
found high bone uptake, which could be due to the fact that
bone marrow lymphocytes are primarily B cells [28].
Moreover, uptake in the lung was also relatively high as a
result of the HLA class II antigens that are constitutively
expressed in lung tissue [29]. We did not collect blood
samples in mice and we did not calculate the blood half-life,
but it has been reported that 1D09C3 has a fast (G3 h) blood
clearance in mice [30]. This characteristic of
99mTc-anti-
HLA-DR mAb makes it distinct from other radiolabelled
mAbs since complete mAbs have predominantly slow blood
clearance from the body [31]. Results of the in vivo targeting
experiments in mice showed that accumulation of radio-
labelled anti-HLA-DR mAb in DAUDI cells was propor-
tional to the number of implanted cells. We also observed an
increase in T/B ratio over time, indicating that imaging at
Fig. 6. a Dorsal scintigraphic images obtained with a high-resolution camera at 6 h in mice xenografted with 10×10
6,2 0 × 1 0
6
or 30×10
6 DAUDI tumour cells in the left shoulder and same number of TPC1 control cells in the right shoulder. Mice were
injected with 10.5–11.5 MBq of
99mTc-anti-HLA-DR mAb. Higher uptake in DAUDI cell xenografts is clearly visible as compared
to DR negative cell xenografts. Regions of interests for T/B ratio calculation are also shown. On the right, a radioactivity scale
has been shown from high to low (top to bottom). b Mean +/− SD of T/B ratios at different time points calculated for three
groups of mice xenografted with increasing number of DAUDI cells. Statistically significant differences (p=G0.05) in T/B ratio
between sequential amounts of cells, 10×10
6 and 20×10
6 (*), 20×10
6 and 30×10
6 (**), 10×10
6 and 30×10
6 (***), are indicated
with asterisk.
Table 1. Increase in T/B ratio over time
No. of injected cells T/B ratio±SD
1h 3h 6h 2 4h
10×10
6 1.17±0.04 1.61±0.05 (p=0.005) 2.33±0.22 (p=0.02) 3.25±0.35 (p=0.04)
20×10
6 1.42±0.09 1.95±0.07 (p=0.01) 2.72±0.12 (p=0.008) 3.92±0.59 (p=0.05)
30×10
6 1.59±0.06 2.90±0.08 (p=0.001) 3.68±0.17 (p=0.01) 4.80±0.42 (p=0.03)
The p value in the brackets indicates a significant difference in T/B ratio, as compared to the previous time point
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isotopes with a longer half-life than technetium-99m may be
applied to radiolabel this mAb for imaging of lymphoma
patients. Interestingly, in vivo blocking of
99mTc-anti-HLA-
DR mAb with a 100-fold molar excess of cold anti-HLA-DR
mAb demonstrated up to 96% specific binding of the
labelled mAb. These experiments show that the newly
radiolabelled mAb is highly specific for HLA-DR in vivo
as well.
Our results are important for possible clinical use of
99mTc-anti-HLA-DR mAb for molecular imaging of major
histocompatibility complex class II protein HLA-DR expres-
sion for diagnostic and prognostic purposes presumably
without any side effects because of its high specific activity.
Indeed, only 67 μg( i.e., 370 MBq) of radiolabelled anti-
HLA-DR mAb should be sufficient for a diagnostic scan in
humans as compared to the very high dose given for therapy
(up to 10 mg/kg/day in an ongoing clinical trial).
Future studies should be focused on the further evaluation
of
99mTc-anti-HLA-DR mAb as a prognostic/diagnostic tool
for imaging HLA-DR positive cell infiltration in patients
affected by B-cell lymphoma/leukemia and autoimmune
inflammatory diseases.
Conclusions
The anti-HLA-DR mAb, 1D09C3, can be efficiently labelled
with technetium-99m for imaging HLA-DR positive cells.
Fig. 7. a Dorsal scintigraphic images at 6 h of mice xenografted with 30×10
6 DAUDI tumour cells mixed with Matrigel in the
left shoulder and with Matrigel only in the right shoulder. Mice were injected with 10.5–11.5 MBq of
99mTc-anti-HLA-DR mAb,
after administration of a 100-fold excess of unlabelled anti-HLA-DR mAb. Regions of interests for T/B calculation are shown.
The left image shows a mouse injected with only labelled mAb (control) and the right image shows a mouse pre-injected with a
100-fold excess of unlabelled anti-DR mAb immediately before the injection of
99mTc-anti-HLA-DR mAb, in the tail vein. The
right image shows almost complete blocking of radiolabelled antibody uptake after pre-injection of cold antibody. On the right
radioactivity scale has been shown from high to low (top to bottom). b Mean +/− SD of T/B ratios calculated for the two groups
of mice xenografted with 30×10
6 DAUDI cells and injected either with a 100-fold excess of unlabelled anti-HLA-DR mAb
immediately before a tracer dose of 10.5–11.5 MBq of
99mTc-anti-DR mAb or only with a tracer dose of
99mTc-anti-HLA-DR
mAb (control). (*P=G0.03).
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99mTc-anti-HLA-DR AntibodyThe labelling method is simple, rapid, reliable and effective,
yielding high specific activity without loss of immune
reactivity. In particular, we were able to demonstrate that
99mTc-anti-HLA-DR mAb targets HLA-DR positive cells in
vivo in Balb/c mice model, and therefore warrants further
evaluation as a prognostic/diagnostic tool in lymphoma
patients or in patients with autoimmune diseases.
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